Antithrombin-lowering in hemophilia: a closer look at fitusiran

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Fitusiran Prophylaxis in Hemophilia With or Without Inhibitors

Hemophilia therapy: the future has begun

Pharmaceuticals, Free Full-Text

Fitusiran Reduces Bleeding in Hemophilia A, B, Regardless of Inhibitors

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation

Monthly injections of fitusiran found to reduce bleeds in patients with hemophilia A and B

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Antithrombin inhibition using nanobodies to correct bleeding in hemophilia

Frontiers Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy